Shaalan Beg/LinkedIn
May 4, 2025, 04:58
Shaalan Beg highlights Emil Lou’s presentation on CRISPR-Cas9-edited T cells targeting CISH in metastatic colorectal cancer at AACR25
Shaalan Beg, Senior Advisor for Clinical Research at the National Cancer Institute (NCI), shared a post on X by Emil Lou, Professor with tenure at the University of Minnesota, adding:
“Exciting early data for new treatment of cancers that are refractory to currently available checkpoint inhibitors.
Targeting immune checkpoint CISH w CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer Emil Lou.”
Authors: Emil Lou et al.
Quoting Emil Lou‘s post:
“It’s not only uncovering what is causing young-adult cases, but also how we can devise better ways to treat it.
At today’s AACR25 session on Innovative Approaches to Key Molecular Targets, I will present work targeting a novel intracellular immune checkpoint using cell therapy.”
Learn more about Shaalan Beg and colorectal cancer on OncoDaily.
AACR25
Ajay Dixit
Akshat Sarkari
Anil Chauhan
Anthony P DeFeo
Beau R Webber
Benjamin Spilseth
Blaine Rathmann
Branden S Moriarity
cancer
Christopher A. Klebanoff
colorectal cancer
Daniel Weber
Darin Sumstad
David H McKenna
Emil Lou
Eric Jensen
Jacob Ankeny
Jason Bell
Jeffrey S. Miller
Jihyun Kim
Katherine Ladner
Madhuri Rao
Mahmoud A Khalifa
Matthew J Johnson
Miranda Byrne-Steele
Modassir S Choudhry
National Cancer Institute
NCI
Nicholas Slipek
OncoDaily
Oncology
Paolo P Provenzano
R Scott McIvor
Shaalan Beg
Thomas A Murray
Timothy D Folsom
Timothy K. Starr
Tom Henley
University of Minnesota
Wenjing Pan
Zhaohui Jin
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 21, 2025, 08:51
May 21, 2025, 08:22
May 21, 2025, 08:07
May 21, 2025, 07:53
May 21, 2025, 07:16